Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 64

recruiting
3 987
countries
28
conditions
2 109

1 221 trials match your criteria

Acute lymphocytic leukaemia

Not recruiting

Study of inotuzumab ozogamicin and drug combination in adult patients with B-cell Acute Lymphoblastic Leukemia who have minimal residual disease before stem cell transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Chronic obstructive pulmonary disease

Not recruiting

Study of tozorakimab effectiveness and safety in former smokers with Chronic Obstructive Pulmonary Disease (COPD) who experience disease flare-ups

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol

Metastatic malignant melanoma

Not recruiting

Study Comparing ABP 206 and Nivolumab for Patients with Unresectable or Metastatic Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab

Triple negative breast cancer

Not recruiting

Study on Avelumab for Patients with High-Risk Triple Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab

Ovarian cancer

Not recruiting

Study on Doxorubicin Hydrochloride and Trabectedin for Patients with Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trabectedin

Multiple sclerosis

Not recruiting

Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Frexalimab

Endocrine ophthalmopathy

Not recruiting

Study on Batoclimab for Treating Patients with Active Thyroid Eye Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab

Prostate cancer metastatic

Not recruiting

Study of Debio 4228 for Patients with Advanced or Metastatic Prostate Cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Degarelix

Non-small cell lung cancer+1

Not recruiting

Study Comparing Zimberelimab and Domvanalimab with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Primary progressive multiple sclerosis

Not recruiting

Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Tolebrutinib

Hodgkin's disease refractory+1

Not recruiting

Study of Pembrolizumab for Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma or Primary Mediastinal Large B-cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Colorectal cancer metastatic+1

Not recruiting

Study of Encorafenib, Cetuximab, and Pembrolizumab for Patients with Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cetuximab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.